Catalyst
Slingshot members are tracking this event:
UltraGenyx (RARE) Expects Data from Phase 2 Seizure Study of UX007 in Glut1 Deficiency Syndrome (Glut1 DS) Patients in Q1 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RARE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 22, 2017
Occurred Source:
http://ir.ultragenyx.com/releasedetail.cfm?ReleaseID=1018416
Related Projects
Related Keywords
Phase 2, Seizure Study, Ux007, Glut1 Deficiency Syndrome, Glut1 Ds
